新诊断转移性前列腺癌前列腺放疗的长期结局
该单中心回顾性队列纳入2005至2015年新诊断转移性激素敏感性前列腺癌(mHSPC)男性410例,其中128例接受前列腺放疗。中位随访61.0个月,接受放疗者总生存(OS)优于未接受者(中位OS 47.4个月对26.3个月),多变量分析仍与OS改善相关。
要点
- 新诊断mHSPC接受前列腺放疗与OS改善相关(多变量HR 0.69,95%CI 0.50-0.94,p=0.02)。
- 接受前列腺放疗者中位OS为47.4个月,未接受者为26.3个月。
- 前列腺放疗剂量越高与OS改善相关(每增加10 Gy,HR 0.87,95%CI 0.76-0.99,p=0.03)。
核心结论
- 在新诊断mHSPC中,接受前列腺放疗与OS改善相关,且获益幅度具有临床意义。
- 前列腺放疗可能存在剂量-反应梯度,值得进一步研究。
研究设计与样本
- 单中心回顾性队列,纳入2005至2015年转诊至综合癌症中心的新诊断mHSPC男性。
- 入组患者初始接受雄激素剥夺治疗,并接受前列腺放疗(BED至少相当于40 Gy/15次)或不接受前列腺放疗。
- 共410例患者,其中128例接受前列腺放疗,中位随访61.0个月。
主要发现
- 单变量分析中,接受前列腺放疗与OS改善相关(HR 0.59,95%CI 0.45-0.77,p=0.0001)。
- 接受前列腺放疗者中位OS为47.4个月,未接受者为26.3个月。
- 多变量Cox模型中,接受前列腺放疗仍与OS改善相关(HR 0.69,95%CI 0.50-0.94,p=0.02)。
- 在接受前列腺放疗者中,BED增加与OS改善相关(每增加10 Gy,HR 0.87,95%CI 0.76-0.99,p=0.03)。
临床怎么用
- 对于新诊断mHSPC患者,可考虑在雄激素剥夺治疗基础上联合前列腺放疗以改善OS。
- 放疗剂量可能影响获益,但需进一步研究确定最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients presenting with metastatic prostate cancer, the role of local therapy is evolving. Two recently reported large-scale randomized trials suggest that radiotherapy (RT) directed at the prostate improves overall survival (OS) in patients with low metastatic burden. We reviewed the experience of prostate RT in this setting at our center. METHODS: The study population consisted of men with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) referred to a comprehensive cancer center between 2005 and 2015 and treated initially with androgen deprivation therapy. Patients were eligible for inclusion if they received (1) prostate RT with biological effective dose (BED) at least that of a course of 40 Gy in 15 fractions or (2) no prostate RT. The association between receipt of prostate RT and OS was studied. OS was estimated using the Kaplan-Meier method and Cox regression was used to identify factors associated with OS. RESULTS: The cohort consisted of 410 patients, of whom 128 received prostate RT. Median follow-up 61.0 months. On univariate analysis, receipt of prostate RT was associated with improved OS (HR 0.59, 95% CI 0.45-0.77, p = 0.0001). Median OS in those patients receiving prostate RT was 47.4 months versus 26.3 months in those not receiving prostate RT. In a multivariate Cox model, receipt of prostate RT remained associated with improved OS (HR 0.69, 95% CI 0.50-0.94, p = 0.02). In those treated with prostate RT, increasing BED was also associated with improved OS (HR 0.87 per 10 Gy increase, 95% CI 0.76-0.99, p = 0.03). CONCLUSIONS: This cohort represents the largest single-center experience of primary tumor-directed RT in mHSPC reported to date. In this population, receipt of prostate RT was associated with improved OS and the magnitude of the OS benefit was clinically significant. The possibility of an RT dose-response gradient in this setting merits further study.
引用
- Morgan SC, Holmes OE, Craig J, et al. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33820949. doi:10.1038/s41391-021-00339-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。